Change in albuminuria and eGFR following insulin sensitization therapy versus insulin provision therapy in the BARI 2D study

Clinical Journal of the American Society of Nephrology

Volumn 9, Issue 1, 2014, Pages 64-71

  August, Phyllis ^a   Hardison, Regina M ^a   Hage, Fadi G ^a   Marroquin, Oscar C ^a   McGill, Janet B ^a   Rosenberg, Yves ^a   Steffes, Michael ^a   Wall, Barry M ^a   Molitch, Mark ^a  

^a WEILL CORNELL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ALBUMIN; CREATININE; GLYCOSYLATED HEMOGLOBIN; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; ROSIGLITAZONE; SULFONYLUREA DERIVATIVE;

ADULT; ALBUMINURIA; ARTICLE; DISEASE COURSE; FEMALE; GLOMERULUS FILTRATION RATE; GLYCEMIC CONTROL; HUMAN; INSULIN PROVISION THERAPY; INSULIN SENSITIZATION THERAPY; INSULIN TREATMENT; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; SENSITIVITY ANALYSIS;

AGED; ALBUMINURIA; BIOLOGICAL MARKERS; CORONARY ARTERY DISEASE; CREATININE; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; DISEASE PROGRESSION; FEMALE; GLOMERULAR FILTRATION RATE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; KIDNEY; LINEAR MODELS; LOGISTIC MODELS; MALE; MIDDLE AGED; ODDS RATIO; RISK FACTORS; TIME FACTORS; TREATMENT OUTCOME;

EID: 84891889333     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.12281211     Document Type: Article

References (24)

1. Berl T, Hunsicker LG, Lewis JB, Pfeffer MA, Porush JG, Rouleau JL, Drury PL, Esmatjes E, Hricik D, Pohl M, Raz I, Vanhille P, Wiegmann TB, Wolfe BM, Locatelli F, Goldhaber SZ, Lewis EJ; Collaborative Study Group: Impact of achieved blood pressure on cardiovascular outcomes in the Irbesartan Diabetic Nephropathy Trial. J Am Soc Nephrol 16: 2170-2179, 2005
2. Pohl MA, Blumenthal S, Cordonnier DJ, De Alvaro F, Deferrari G, Eisner G, Esmatjes E, Gilbert RE, Hunsicker LG, de Faria JB, Mangili R, Moore J Jr., Reisin E, Ritz E, Schernthaner G, Spitalewitz S, Tindall H, Rodby RA, Lewis EJ: Independent and additive impact of blood pressure control and angiotensin II receptor blockade on renal outcomes in the irbesartan diabetic nephropathy trial: Clinical implications and limitations. J AmSoc Nephrol 16: 3027-3037, 2005
3. de Boer IH, Sun W, Cleary PA, Lachin JM, Molitch ME, Steffes MW, Zinman B; DCCT/EDIC ResearchGroup: Intensive diabetes therapy and glomerular filtration rate in type 1 diabetes. N Engl J Med 365: 2366-2376, 2011
4. Bolignano D, Zoccali C: Glitazones in chronic kidney disease: Potential and concerns. NutrMetab Cardiovasc Dis 22: 167-175, 2012
5. Brooks MM, Frye RL, Genuth S, Detre KM, Nesto R, Sobel BE, Kelsey SF, Orchard TJ; Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial Investigators: Hypotheses, design, and methods for the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial. Am J Cardiol 97[Suppl 12A]: 9G-19G, 2006
6. Frye RL, August P, Brooks MM, Hardison RM, Kelsey SF, MacGregor JM, Orchard TJ, Chaitman BR, Genuth SM, Goldberg SH, Hlatky MA, Jones TL, Molitch ME, Nesto RW, Sako EY, Sobel BE; BARI 2D Study Group: A randomized trial of therapies for type 2 diabetes and coronary artery disease. N Engl J Med 360: 2503-2515, 2009
7. Wall BM, Hardison RM, Molitch ME, Marroquin OC, McGill JB, August PA; BARI 2D Study Group: High prevalence and diversity of kidney dysfunction in patients with type 2 diabetes mellitus and coronary artery disease: The BARI 2D baseline data. Am J Med Sci 339: 401-410, 2010
8. Bypass Angioplasty Revascularization Investigation 2 Diabetes Study Group: Baseline characteristics of patients with diabetes and coronary artery disease enrolled in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial. Am Heart J 156: 528-536, 2008
9. Levey AS, Bosch JP, Lewis JB, Greene T, Rogers N, Roth D; Modification of Diet in Renal Disease Study Group: A more accurate method to estimate glomerular filtration rate from serum creatinine: A new prediction equation. Ann Intern Med 130: 461-470, 1999
10. Stevens LA, Greene T, Levey AS: Surrogate end points for clinical trials of kidney disease progression. Clin J Am Soc Nephrol 1: 874-884, 2006
11. Mattix HJ, Hsu CY, Shaykevich S, Curhan G: Use of the albumin/ creatinine ratio to detect microalbuminuria: Implications of sex and race. J Am Soc Nephrol 13: 1034-1039, 2002
12. Gerstein HC, Mann JF, Yi Q, Zinman B, Dinneen SF, Hoogwerf B, Hallé JP, Young J, Rashkow A, Joyce C, Nawaz S, Yusuf S; HOPE Study Investigators: Albuminuria and risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 286: 421-426, 2001
13. Hedeker D, Gibbons RD: Application of random-effects patternmixture models for missing data in longitudinal studies. Psychol Methods 2: 64-78, 1997
14. Nissen SE, Nicholls SJ, Wolski K, Nesto R, Kupfer S, Perez A, Jure H, De Larochellière R, Staniloae CS, Mavromatis K, Saw J, Hu B, Lincoff AM, Tuzcu EM; PERISCOPE Investigators: Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: The PERISCOPE randomized controlled trial. JAMA 299: 1561-1573, 2008
15. Sobel BE, Hardison RM, Genuth S, Brooks MM, McBane RD 3rd, Schneider DJ, Pratley RE, Huber K, Wolk R, Krishnaswami A, Frye RL; BARI 2D Investigators: Profibrinolytic, antithrombotic, and antiinflammatory effects of an insulin-sensitizing strategy in patients in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial. Circulation 124: 695-703, 2011
16. Ohga S, Shikata K, Yozai K, Okada S, Ogawa D, Usui H, Wada J, Shikata Y, Makino H: Thiazolidinedione ameliorates renal injury in experimental diabetic rats through anti-inflammatory effects mediated by inhibition of NF-kappaB activation. Am J Physiol Renal Physiol 292: F1141-F1150, 2007
17. Yang J, Zhang D, Li J, Zhang X, Fan F, Guan Y: Role of PPARgamma in renoprotection in Type 2 diabetes: Molecular mechanisms and therapeutic potential. Clin Sci (Lond) 116: 17-26, 2009
18. Baylis C, Atzpodien EA, Freshour G, Engels K: Peroxisome proliferator-activated receptor [gamma] agonist provides superior renal protection versus angiotensin-converting enzyme inhibition in a rat model of type 2 diabetes with obesity. J Pharmacol Exp Ther 307: 854-860, 2003
19. McCarthy KJ, Routh RE, Shaw W, Walsh K, Welbourne TC, Johnson JH: Troglitazone halts diabetic glomerulosclerosis by blockade of mesangial expansion. Kidney Int 58: 2341-2350, 2000
20. Kobayashi H, Tokudome G, Hara Y, Sugano N, Endo S, Suetsugu Y, Kuriyama S, Hosoya T: Insulin resistance is a risk factor for the progression of chronic kidney disease. Clin Nephrol 71: 643-651, 2009
21. Agrawal V, Shah A, Rice C, Franklin BA, McCullough PA: Impact of treating the metabolic syndrome on chronic kidney disease. Nat Rev Nephrol 5: 520-528, 2009
22. Bakris G, Viberti G, Weston WM, Heise M, Porter LE, Freed MI: Rosiglitazone reduces urinary albumin excretion in type II diabetes. J Hum Hypertens 17: 7-12, 2003
23. Sarafidis PA, Stafylas PC, Georgianos PI, Saratzis AN, Lasaridis AN: Effect of thiazolidinediones on albuminuria and proteinuria in diabetes: Ameta-analysis. AmJ KidneyDis 55: 835-847, 2010
24. Lachin JM, Viberti G, Zinman B, Haffner SM, Aftring RP, Paul G, Kravitz BG, Herman WH, Holman RR, Kahn SE; ADOPT Study Group: Renal function in type 2 diabetes with rosiglitazone, metformin, and glyburide monotherapy. Clin J Am Soc Nephrol 6: 1032-1040, 2011